E2A/PBX1/HLF Translocation, Dual Fusion
The E2A (TCF3) gene is involved in recurrent rearrangements in childhood Acute Lymphoblastic Leukaemia (ALL)1. Two known partner genes are the Pre-B-cell Leukaemia Homeobox 1 gene (PBX1, chromosome 1q23.3) and the Hepatic Leukaemia Factor gene (HLF, chromosome 17q22), which become fused to E2A as a result of translocations, forming the E2A/PBX12and E2A/HLF fusion proteins, respectively3.
The 2011 Acute Lymphoblastic Leukaemia Best Practice Guidelines state that “when TCF3 ‘breakapart’ FISH identifies a rearrangement, it is important to distinguish between t(17;19)(q22;p13) and t(1;19)(q23;p13), the former translocation being associated with adverse prognosis”4.
Cytocell provides a range of probes that allow flexibility in screening for E2A (TCF3) rearrangements: the E2A (TCF3) Breakapart probe (LPH 019), the E2A/PBX1 Translocation, Dual Fusion probe (LPH 079) and the E2A/PBX1/HLF Translocation, Dual Fusion probe (LPH 080), a 3 colour probe that allows both E2A/PBX1 and E2A/HLF fusions to be detected.
1. LeBrun. Front Biosci. 2003 May 1;8:s206-22
2. Alonso CN. t(1;19)(q23;p13) TCF3/PBX1. Atlas Genet Cytogenet Oncol Haematol. July 2012
3. Viguié F. t(17;19)(q22;p13). Atlas Genet Cytogenet Oncol Haematol. May 1999
4. Professional Guidelines for Clinical Cytogenetics: ACUTE LYMPHOBLASTIC LEUKAEMIA BEST PRACTICEGUIDELINES (2011) V1.00. www.cytogenetics.org.uk
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.